Clinical studies of p53 in treatment and benefit of breast cancer patients

Endocrine-Related Cancer

Volumn 6, Issue 1, 1999, Pages 51-59

  Bergh, J ^a,b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANALYTIC METHOD; ARTICLE; BREAST CANCER; CELL FUNCTION; CYTOSTASIS; GENE CONTROL; GENE MUTATION; HUMAN; MEDICAL LITERATURE; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ESTROGENS; FEMALE; GENES, ERBB-2; GENES, P53; GENES, RAS; HUMANS; MIDDLE AGED; MULTIGENE FAMILY; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE; PROGNOSIS; SURVIVAL ANALYSIS; TRANSFECTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032894510     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060051     Document Type: Article

References (76)

1. Aas T, Børresen A-L, Geisler S, Smith-Sørensen B, Johansen H, Varhaug J, Akslen L & Lønning P 1996 Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine 2811-814.
2. Allred D, Clark G, Elledge R, Fuqua S, Brown R, Chamness G, Osborne C & McGuire w 1993 Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. Journal of the National Cancer Institute 85 200-206.
3. Andersen T, Holm R, Nesland J, Heimdal K, Ottestad L & Børresen A-L 1993 Prognostic significance of TP53 alterations in breast carcinoma. British Journal of Cancer 68 540-548.
4. Archer S, Eliopoulos A, Spandidos D, Barnes D, Ellis I, Blamey R, Nicholson R & Robertson J 1995 Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. British Journal of Cancer 72 1259-1266.
5. Barnes D, Dublin E, Fisher C, Levison D & Millis R 1993 Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis. Human Pathology 24 469-476.
6. Beck W & Dalton W 1997 Mechanisms of drug resistance. In Cancer: Principles and Practise of Oncology, edn 5, pp 498-512. Eds V DeVita, S Hellman & S Rosenberg. Philadelphia/New York: Lippincott-Raven Publishers.
7. Bergh J 1997 Time for integration of predictive factors for selection of breast cancer patients who need postoperative radiation? Journal of the National Cancer Institute 89 605-607.
8. Bergh J 1998a Importance of p53 in the diagnosis and treatment of cancer. Educational book, pp 179-186. 23rd ESMO Congress, Athens, Greece.
9. Bergh J 1998b Tailored chemotherapy to equal toxicity - is it possible? In Adjuvant Therapy of Primary Breast Cancer, edn, pp 328-340. Eds H-J Senn, R Gelber, A Goldhirsch & B Thürlimann. Berlin/Heidelberg/New York: Springer-Verlag.
10. Bergh J, Norberg T, Sjögren S, Lindgren A & Holmberg L 1995 Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine 1 1029-1034.
11. Berns E, Klijn J, van Putten W, de Witte H, Look M, Meijer-van Gelder M, Willman K, Portengen H, Benraad T & Foekens J 1998 p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. Journal of Clinical Oncology 16 121-127.
12. Børresen A-L, Ikdahl Andersen T, Eyfjörd J, Cornelis R, Thorlacius S, Borg Å, Johanson U, Theillet C, Scherneck S, Hartman S, Cornelisse C, Hovig E & Devilee P 1995 TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes, Chromosomes and Cancer 14 71-75.
13. Børresen-Dale A 1997 Subgroups of p53 mutations may predict the clinical behaviour of cancers in the breast and colon and contribute to therapy response. In Prognostic and Predictive Value of p53, pp 23-33. Ed J Klijn. Amsterdam: Elsevier Science BV.
14. Burke H, Hoang A, Iglehart J & Marks J 1998 Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 82 874-877.
15. Callahan R 1992 p53 mutations, another breast cancer prognostic factor. Journal of the National Cancer Institute 84 826-827.
16. Cattoretti G, Rilke F, Andreola S, D'Amato L & Delia D 1988 p53 expression in breast cancer. International Journal of Cancer 41 178-183.
17. Chin K, Ueda K, Pastan I & Gottesman M 1992 Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255 459-255.
18. Clahsen P, van de Velde C, Duval C, Pallud C, Mandard A, Delobelle-Deroide A, van den Broek L, Sahmoud T & van de Vijver M 1998 p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. Journal of Clinical Oncology 16 470-479.
19. Clarke A, Purdie C, Harrison D, Morris R, Bird C, Hooper M & Wyllie A 1993 Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature 362 849-852.
20. Degeorges A, de Roquancourt A, Extra J, Espie M, Bourstyn E, de Cremoux P, Soussi T & Marty M 1998 Is p53 a protein that predicts the response to chemotherapy in node-negative breast cancer? Breast Cancer Research and Treatment 47 47-55.
21. Delia D, Mizutani S, Lamorte G, Goi K, Iwata S & Pierotti M 1996 p53 activity and chemotherapy. Nature Medicine 2 724-725.
22. Dittmer D, Pati S, Zambetti G, Chu S, Teresky A, Moore M, Finlay C & Levine A 1993 Gain of function mutations in p53. Nature Genetics 4 42-46.
23. Dublin E, Miles D, Rubens R, Smith P & Barnes D 1997 p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer. International Journal of Cancer 74 605-608.
24. Elledge R 1996 Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? Journal of the National Cancer Institute 88 141-143.
25. Elledge R, Fuqua S, Clark G, Pujol P, Allred D & McGuire W 1993 Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Research and Treatment 26 225-235.
26. Elledge R, Lock-Lim S, Allred D, Hilsenbeck S & Cordner L 1995 p53 mutation and tamoxifen resistance in breast cancer. Clinical Cancer Research 1 1203-1208.
27. Elledge R, Green S, Howes L, Clark G, Berardo M, Allred D, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S & Osborne C 1997 bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group Study. Journal of Clinical Oncology 15 1916-1922.
28. Fan S, El-Deiry W, Bae I, Freeman J, Jondle D, Bhatia K, Fornace A Jr, Magrath I, Kohn K & O'Connor P 1994 p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Research 54 5824-5830.
29. Formenti S, Dunnington G, Uzieli B, Lenz H, Keren-Rosenberg S, Silberman H, Spicer D, Denk M, Leichman G, Groshen S, Watkins K, Muggia F, Florentine B, Press M, Danenberg K & Danenberg P 1997 Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion of 5-fluorouracil and radiation therapy. International Journal of Radiation Oncology, Biology, Physics 39 1059-1068.
30. Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M & Tominaga T 1998 Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. International Journal of Oncology 12 1117-1125.
31. Graeber T, Peterson J, Tsai M, Monica K, Fornace Jr A & Giaccia A 1994 Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Molecular and Cellular Biology 14 6264-6277.
32. Halevy O, Michalovitz D & Oren M 1990 Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250 113-116.
33. Harris C 1996 Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. Journal of the National Cancer Institute 88 1442-1455.
34. Hawkins D, Demers G & Galloway D 1996 Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Research 56 892-898.
35. Houldsworth J, Xiao H, Murty V, Chen W, Ray B, Reuter V, Bosl G & Chaganti R 1998 Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16 2345-2349.
36. Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L & Bergh J 1995 p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. Journal of Clinical Oncology 13 2745-2751.
37. Jost C, Marin M & Kaelin Jr W 1997 p73 is a human p53-related protein that can induce apoptosis [see comments]. Nature 389 191-194.
38. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J, Valent A, Minty A, Chalon P, Lelias J, Dumont X, Ferrara P, McKeon F & Caput D 1997 Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 809-819.
39. Kirsch D & Kastan M 1998 Tumor-suppressor p53: implications for tumor development and prognosis. Journal of Clinical Oncology 16 3158-3168.
40. Koechli O, Schaer G, Seifert B, Hornung R, Haller U, Eppenberger U & Mueller H 1994 Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344 1647-1648.
41. Lane D 1992 p53, guardian of the genome. Nature 358 15-16.
42. Larsson L, Carlsson G, Sjögren S, Holmberg L, Rudenstam C-M, Gustavsson B, InganaØs M & Bergh J 1999 Mutations in the p53 gene predict the clinical outcome of adjuvant therapy in node-positive patients with early breast cancer. Submitted to 35th ASCO Annual Meeting. Atlanta, Georgia.
43. Li R, Sutphin R, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M & Rotter V 1998 Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 16 3269-3277.
44. Lim J, Ly A, Bhimani R, Frenkel K & Troll W 1994 The chemopreventive agent tamoxifen causes apoptosis. 85th Annual Meeting of the American Association for Cancer Research, San Francisco, CA, USA. p 619 (abstract 3693).
45. Linn S, Pinedo H, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop A, Vermorken J & Giaccone G 1997 Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. International Journal of Cancer 71 787-795.
46. Liu W & Zhang R 1998 Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural products anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and -independent pathways. International Journal of Oncology 12 793-804.
47. Lowe S, Ruley H, Jacks T & Housman D 1993 p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 957-967.
48. Lowe S, Bodis S, McClatchey A, Remington L, Ruley H, Fisher D, Housman D & Jacks T 1994 p53 status and the efficacy of cancer therapy in vivo. Science 266 807-810.
49. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I & Coindre M 1996 Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB 1, pS2 and GST pi. British Journal of Cancer 74 1458-1465.
50. Makris A, Powles T, Dowsett M & Allred C 1995 p53 protein overexpression and chemosensitivity in breast cancer. Lancet 345 1181-1182.
51. Makris A, Powles T, Dowsett M, Osborne C, Trott P, Fernando I, Ashley S, Ormerod M, Titley J, Gregory R & Allred D 1997 Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clinical Cancer Research 3 593-600.
52. Mathieu M-C, Koscielny S, Le Bihan M-C, Spielmann M & Arriagada R 1995 p53 protein overexpression and chemosensitivity in breast cancer. The Lancet 345 1182.
53. Milne D, Palmer R & Meek D 1992 Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. Nucleic Acids Research 20 5565-5570.
54. Mukhopadhyay T & Roth J 1993 A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Research 53 4362-4366.
55. Niskanen E, Blomqvist C, Franssila K, Hietanen P & Wasenius V 1997 Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. British Journal of Cancer 76 917-922.
56. Norberg T, Lennerstrand J, Inganäs M & Bergh J 1998 Comparison between p53 protein measurement using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumours. International Journal of Cancer 79 376-383.
57. O'Connor P, Jackman J, Jondle D, Bhatia K, Magrath I & Kohn K 1993 Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Research 53 4776-4780.
58. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamura R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M & Ikawa S 1998 Cloning and functional analysis of human p53, which structurally and functionally resembles p53. Nature Medicine 4 839-843.
59. Roodi N, Bailey L, Kao W, Verrier C, Yee C, Dupont W & Parl F 1995 Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. Journal of the National Cancer Institute 87 446-451.
60. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, Nieruchalski M, Fourquet A, Clough K, Dieras V, Pouillart P & Sastre-Garau X 1998 No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. International Journal of Cancer 79 27-33.
61. Serrano M, Lin A, McCurrach M, Beach D & Lowe S 1997 Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 593-602.
62. Silvestrini R 1996 Re the p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. Journal of the National Cancer Institute 88 1499.
63. Silvestrini R, Benini E, Daidone M, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G & Veronesi U 1993 p53 as an independent prognostic marker in lymph node-negative breast cancer patients. Journal of the National Cancer Institute 85 965-970.
64. Silvestrini R, Daidone M, Benini E, Faranda A, Tomasic G, Boracchi P, Salvadori B & Veronesi U 1996 Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clinical Cancer Research 2 2007-2013.
65. Silvestrini R, Veneroni S, Benini E, Daidone M, Luisi A, Leutner M, Maucione A, Kenda R, Zucali R & Veronesi U 1997 Expression of p53, glutathione S-transferase-π, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. Journal of the National Cancer Institute 89 639-645.
66. Sjögren S 1997 Prognostic factors with predictive potential in breast cancer. Special focus on the tumour suppressor p53. Acta Universitatis Upsaliensis, Uppsala. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, no. 722.
67. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L & Bergh J 1996 The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. Journal of the National Cancer Institute 88 173-182.
68. Sjöström J, Krajewski S, Franssila K, Niskanen E, Wasenius W, Nordling S, Reed J & Blomqvist C 1998 A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. British Journal of Cancer 78 812-815.
69. Thor A & Yandell D 1993 Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. Journal of the National Cancer Institute 85 176-177.
70. Thor A, Berry D, Budman D, Muss H, Kute T, Henderson I, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L & Liu E 1998 erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute 90 1346-1360.
71. Trink B, Okami K, Wu L, Sriuranpong V, Jen J & Sidransky D 1998 A new human p53 homologue. Nature Medicine 4 747-748.
72. Wahl A, Donaldson K, Fairchild C, Lee F, Foster S, Demers W & Galloway D 1996 Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Medicine 2 72-79.
73. Williams C, Norberg T, Ahmadian A, Pontén F, Bergh J, Inganäs M, Lundeberg J & Uhlén M 1998 Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. Clinical Chemistry 44 455-462.
74. Wu G & El-Deiry W 1996 p53 and chemosensitivity. Nature Medicine 2 255-256.
75. Xia F, Wang X, Wang Y-H, Tsang N-M, Yandell D, Kelsey K & Liber H 1995 Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Research 55 12-15.
76. Zastawny R, Salvino R, Chen J, Benchimol S & Ling V 1993 The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8 1529-1535.